A Bayesian Framework for Patient-Level Partitioned Survival Cost-Utility Analysis

Author:

Gabrio Andrea1ORCID

Affiliation:

1. Department of Statistical Science, University College London, London, UK

Abstract

Patient-level health economic data collected alongside clinical trials are an important component of the process of technology appraisal. For end-of-life treatments, the modeling of cost-effectiveness data may involve some form of partitioned survival analysis, in which measures of quality of life and survival for pre- and postprogression periods are combined to generate aggregate measures of clinical benefits (e.g., quality-adjusted survival). In addition, resource use data are often collected and costs are calculated for each type of health service (e.g., treatment, hospital, or adverse events costs). A critical problem in these analyses is that effectiveness and cost data present some complexities, such as nonnormality, spikes, and missingness, which should be addressed using appropriate methods to avoid biased results. This article proposes a general Bayesian framework that takes into account the complexities of trial-based partitioned survival cost-utility data to provide more adequate evidence for policy makers. Our approach is motivated by, and applied to, a working example based on data from a trial assessing the cost-effectiveness of a new treatment for patients with advanced non–small-cell lung cancer. [Box: see text]

Publisher

SAGE Publications

Subject

Health Policy

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3